Mesa Laboratories, Inc. Share Price
Equities
MLAB
US59064R1095
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
103.2 USD | +1.37% | +2.43% | -1.51% |
Sales 2024 * | 212M 17.65B | Sales 2025 * | 235M 19.59B | Capitalization | 557M 46.41B |
---|---|---|---|---|---|
Net income 2024 * | - 0 | Net income 2025 * | 2M 167M | EV / Sales 2024 * | 2.63 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.37 x |
P/E ratio 2024 * |
-1,876
x | P/E ratio 2025 * |
275
x | Employees | 698 |
Yield 2024 * |
0.62% | Yield 2025 * |
0.62% | Free-Float | 94.26% |
1 day | +1.37% | ||
1 week | +2.43% | ||
Current month | -5.96% | ||
1 month | -3.79% | ||
3 months | +8.61% | ||
6 months | +6.91% | ||
Current year | -1.51% |
Managers | Title | Age | Since |
---|---|---|---|
Gary Owens
CEO | Chief Executive Officer | 56 | 20/17/20 |
John Sullivan
CHM | Chairman | 71 | 01/04/01 |
John Sakys
DFI | Director of Finance/CFO | 55 | 29/12/29 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Sullivan
CHM | Chairman | 71 | 01/04/01 |
Mark Capone
BRD | Director/Board Member | 61 | 05/01 |
R. Tripeny
BRD | Director/Board Member | 65 | 23/22/23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 103.2 | +1.37% | 19,542 |
25/24/25 | 101.8 | -2.56% | 24,278 |
24/24/24 | 104.5 | -2.02% | 19,558 |
23/24/23 | 106.6 | +4.26% | 34,374 |
22/24/22 | 102.3 | +1.51% | 36,134 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.51% | 557M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- MLAB Stock